CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe
DOI 10.1055/s-0035-1559176
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Welzel, J Petersen, M Gschwantler, M Cornberg, A Zoufaly, T Berg, U Naumann, M Van der Valk, O Weiland, M Jimenez-Exposito, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Einleitung: Treatment of HCV genotype 3 (GT3) infection remains a high medical need. Compared to HCV non-GT3, pts with HCV GT3 have faster rates of fibrosis progression, higher prevalence of severe steatosis, and a higher incidence of hepatocellular carcinoma. Treatment options for HCV GT3 pts are limited, and debate continues on the optimal regimen and duration of treatment, especially in those with cirrhosis. This…
Zitieren
Zitierempfehlung
T Welzel, J Petersen, M Gschwantler, M Cornberg, A Zoufaly, T Berg, U Naumann, M Van der Valk, O Weiland, M Jimenez-Exposito, S Zeuzem (2015) Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0035-1559176
Mit CareLit weiterarbeiten